Health technology assessment (HTA) agency NICE has finalised its guidance on Amarin's Vazkepa, clearing the path for GPs to start prescribing the drug in up to 425,000 NHS patients at high
Cost-effectiveness watchdog NICE has recommended routine NHS use of two new therapies for women with advanced breast cancer – Gilead's Trodelvy and Novartis' Piqray – in England.
NICE has updated its recommendations for NHS use of Johnson & Johnson's IL-23 inhibitor Tremfya in the treatment of psoriatic arthritis (PsA), expanding the pool of patients eligible fo
NICE has recommended routine use of Bristol-Myers Squibb's Opdivo for the adjuvant treatment of some patients with urothelial carcinoma (UC), the most common form of bladder cancer.
Thousands more people with breast cancer in England look set to be eligible for routine treatment with Eli Lilly's Verzenios, after new guidance from NICE backed use of the drug after surge
